QC
ABUS icon

QCM Cayman’s Arbutus Biopharma ABUS Stock Holding History

QCM Cayman’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,205
Closed -$40K – 86
2021
Q4 		$40K Buy
+10,205
New +$39.6K 0.24% 62
2021
Q2 		– Sell
-12,728
Closed -$42K – 118
2021
Q1 		$42K Buy
+12,728
New +$49.1K 0.13% 101

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

QCM Cayman's ABUS Position: Q1 2022 in Review

QCM Cayman sold out of Arbutus Biopharma (ABUS) in Q1 2022, closing a stake of 10,205 shares — an estimated $40K sold.

QCM Cayman first reported a position in ABUS in Q1 2021 and held it in 2 quarters. The position peaked at $42K in Q1 2021. 119 funds tracked by Wall St. Rank hold ABUS as of Q1 2022.

  • QCM Cayman reported no remaining Arbutus Biopharma position as of Q1 2022 after selling out during the quarter.
  • QCM Cayman sold 10,205 Arbutus Biopharma shares in Q1 2022, an estimated $40K.
  • QCM Cayman first reported a position in Arbutus Biopharma in Q1 2021 and held it in 2 quarters.
  • QCM Cayman's Arbutus Biopharma position peaked at $42K in Q1 2021.
  • 119 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2022.

Based on QCM Cayman's 13F filing for Q1 2022, filed 6 May 2022.